Sodium-Glucose Cotransporter 2 Inhibitors Increase Risk for Falls in Patients With Diabetes
By Lori Solomon HealthDay Reporter
WEDNESDAY, April 30, 2025 -- Sodium-glucose cotransporter 2 (SGLT2) inhibitor use is an independent risk factor for falls in people with type 2 diabetes, according to a study published online March 17 in Scientific Reports.
Yasuhiro Suzuki, from University of Tsukuba in Japan, and colleagues examined the association of SGLT2 inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists with falls in patients with type 2 diabetes. The analysis included annual fall survey responses from 471 participants with a median age of 64 years during a median period of two years.
The researchers found that the overall fall incidence rate was 17.1 per 100 person-years. Fall history, SGLT2 inhibitor use, and age were independent fall predictors. For using SGLT2 inhibitors only or GLP-1 receptor agonists and SGLT2 inhibitors combined, odds of falling were heightened (odds ratios, 1.80 and 2.89, respectively). However, the association was not significant for GLP-1 receptor agonists only.
"SGLT2 inhibitor use was an independent risk factor for falls, while GLP-1 receptor agonists' effects were not statistically significant. However, the combined use of SGLT2 inhibitors and GLP-1 receptor agonists significantly increased the risk of falls," the authors write. "Therefore, it is important to consider this risk when prescribing these medications to people with type 2 diabetes."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted April 2025
Read this next
Topical Testosterone + Exercise No Aid for Hip Fracture Recovery in Women
TUESDAY, May 20, 2025 -- Topical testosterone therapy does not significantly improve functional outcomes beyond supervised exercise training in older women recovering from a hip...
GLP-1 Receptor Agonists Not Linked to Increased Risk of Psychiatric Adverse Events, Depression
MONDAY, May 19, 2025 -- For patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is not associated with an increased...
Air Pollution May Worsen Bone Health in Postmenopausal Women
FRIDAY, May 16, 2025 -- Exposure to air pollution may worsen bone loss in postmenopausal women, according to a study published online April 24 in the Journal of Bone and...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.